The study aims to determine whether MZGCY inhibits inflammation in CKD rats’ kidneys and intestines by regulating the TLR4/MyD88/NF-κB signaling pathway, thereby providing a novel approach for CKD treatment. Here, TLR4 is linked to chronic kidney disease.